Table 5.

Ongoing clinical trials combining CTLA-4 with PD-1/PD-L1 blockade.

Agent	Phase (n)	Indication	Reference
Tremelimumab*	1 (19)	AST	NCT02718911, NCT02141347, NCT01938612, NCT01975831, NCT02537418, NCT02643303, NCT02658214, NCT02261220
		Others	NCT03005002, NCT02754856, NCT02262741, NCT02117219, NCT02549651, NCT02000947, NCT02311361, NCT02812420, NCT03132467, NCT03085849, NCT03122496
	1b/2 (8)	All	NCT02978482, NCT02735239, NCT02340975, NCT02821754, NCT02499328, NCT02535078, NCT03116529, NCT03019003
	2 (29)	Breast	NCT02536794, NCT02997995, NCT02527434
		Pancreatic	NCT02558894, NCT02879318, NCT02527434
		Others	NCT02879162, NCT02938793, NCT02870920, NCT02888743, NCT02794883, NCT02519348, NCT02319044, NCT02588131, NCT02592551, NCT02788773, NCT02819596, NCT02815995, NCT02937818, NCT02701400, NCT02527434, NCT03046862, NCT03101475, NCT03081923, NCT03015129, NCT03075527, NCT03130764, NCT03095274, NCT03057106, NCT03026062, NCT03022500
	3 (8)	NSCLC	NCT02352948, NCT02453282, NCT02542293
		Others	NCT02516241, NCT02369874, NCT02551159, NCT03084471, NCT03043872
Ipilimumab*	1 (25)	Melanoma	NCT02723006, NCT01024231, NCT01621490, NCT01940809, NCT02639026, NCT02659540, NCT02437279, NCT01176474
		Hematologic	NCT01896999, NCT01592370, NCT02716805, NCT02879695, NCT02846376, NCT01822509
		Others	NCT02174172, NCT02408861, NCT02453620, NCT02833233, NCT01840579, NCT02635061, NCT01472081, NCT02210117, NCT02496208, NCT03044613, NCT03026166
	1b/2 (19)	Melanoma	NCT02259231, NCT02736123, NCT02857569, NCT02941744, NCT02913417, NCT02990611, NCT02089685
		Others	NCT02681302, NCT02039674, NCT02933255, NCT02089685, NCT02304458, NCT01928394, NCT02488759, NCT01658878, NCT03110107, NCT03126110, NCT03048136, NCT03138161, NCT03043599
	2 (53)	Melanoma	NCT01585194, NCT01783938, NCT01927419, NCT02320058, NCT02519322, NCT02523313, NCT02626962, NCT02656706, NCT02731729, NCT02970981, NCT02977052, NCT02978443, NCT02631447, NCT02968303, NCT02374242, NCT02939300, NCT02553642, NCT03033576, NCT03126461, NCT03122522
		NSCLC	NCT03083691, NCT03001882, NCT02350764, NCT02659059, NCT03091491
		RCC	NCT03029780, NCT03117309, NCT03065179, NCT02996110, NCT02960906, NCT02917772, NCT03075423
		Others	NCT02923934, NCT02834013, NCT02892734, NCT02060188, NCT02935634, NCT02880020, NCT02823574, NCT02919683, NCT02716272, NCT02530463, NCT02866383, NCT02985957, NCT02601014, NCT02982486, NCT02046733, NCT02553642, NCT03101566, NCT03130959, NCT03097939, NCT03071406, NCT03061539, NCT03104439
	3 (22)	Melanoma	NCT01844505, NCT02224781, NCT02388906, NCT02460068, NCT02599402, NCT02714218, NCT02905266, NCT02339571, NCT03068455
		NSCLC	NCT02477826, NCT02785952, NCT02864251, NCT02869789, NCT02998528
		Others	NCT02872116, NCT02017717, NCT02741570, NCT02231749, NCT02538666, NCT02982954, NCT02899299, NCT03036098

^*Some trials are enrolling multiple tumor types and were listed twice. Abbreviations: AST = advanced solid tumors, CTLA-4 = cytotoxic T-lymphocyte associated protein-4, NSCLC = non-small cell lung cancer, RCC = renal cell carcinoma.